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ABSTRACT:
The absorption, metabolism, and excretion of imidafenacin [KRP-
197/ONO-8025, 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutana-
mide], a new antimuscarinic drug developed for treatment of over-
active bladder, were assessed in six healthy male subjects after a
single oral administration of 0.25 mg of [14C]imidafenacin (approx-
imately 46 Ci). The highest radioactivity in the plasma was ob-
served at 1.5 h after administration. The apparent terminal elimi-
nation half-life of the total radioactivity was 72 h. Approximately
65.6 and 29.4% of the administered radioactivity were recovered in
the urine and feces, respectively, within 192 h after administration.
The metabolite profiling by high-performance liquid chromatogra-
phy-radiodetector and liquid chromatography/tandem mass spec-
trometry demonstrated that the main component of radioactivity
was unchanged imidafenacin in the 2-h plasma. The N-glucuronide
conjugate (M-9) was found as the major metabolite and the oxi-
dized form of the 2-methylimidazole moiety (M-2) and the ring-
cleavage form (M-4) were detected as the minor metabolites in the
2-h plasma, but M-4 was found to be the main component in the
12-h plasma. Unchanged imidafenacin, M-9, M-2, and other oxi-
dized metabolites were excreted in the urine, but the unchanged
imidafenacin and M-9 were not found in the feces. Two unique
metabolites were found in the urine and feces, which were identi-
fied as the interchangeable cis- and trans-isomers of 4,5-dihydro-
diol forms of the 2-methylimidazole moiety. These findings indicate
that imidafenacin is rapidly and well absorbed (at least 65% of
dose recovered in urine) after oral administration, circulates in
human plasma as the unchanged form, its glucuronide, and other
metabolites, and is then excreted in urine and feces as the oxidized
metabolites of 2-methylimidazole moiety.
Imidafenacin [KRP-197/ONO-8025, 4-(2-methyl-1H-imidazol-1-
yl)-2,2-diphenylbutanamide] (Fig. 1) is a newly synthesized antimus-
carinic drug developed for treatment of overactive bladder. Acetyl-
choline is well known for playing a major role in contracting the
bladder through activation of muscarinic receptors (Somogyi and de
Groat, 1992; Wang et al., 1995; Braverman et al., 1998). Compounds
with high affinity for the muscarinic acetylcholine receptor, including
propiverine, tolterodine, oxybutynin, darifenacin, and solifenacin,
have been used in management of overactive bladder (Chapple et al.,
2002; Andersson and Yoshida, 2003; Andersson, 2004; Robinson and
Cardozo, 2005). Imidafenacin showed high in vitro affinity for mus-
carinic receptor subtypes M1 and M3 in the functional assay using
isolated animal tissues and in the binding assay using recombinant
human receptors (Miyachi et al., 1999; Kobayashi et al., 2007a). In
addition, imidafenacin inhibited carbachol-induced contraction of iso-
lated guinea pig and human bladder mediated by the M3 receptor and
acetylcholine release from isolated rat and human bladder mediated
by the prejunctional M1 receptor (Murakami et al., 2003; Kobayashi
et al., 2007a). A carbachol-induced reduction in bladder capacity and
distention-induced rhythmic bladder contraction were prevented by
imidafenacin dose dependently in conscious rats (Miyachi et al., 1999;
Kobayashi et al., 2007b). On the other hand, the effects of imidafe-
nacin on carbachol-induced salivary gland secretion mediated by M3
receptor alone were less potent than those on bladder contraction in
rats (Miyachi et al., 1999; Kobayashi et al., 2007b).
In the pharmacokinetic assays in the preclinical toxicology studies,
imidafenacin was absorbed rapidly with absolute bioavailability of
5.6% in rats and 36.1% in dogs after oral administration (Masuda et
al., unpublished observations). Orally administered [14C]imidafenacin
was excreted as many metabolites in the feces, and the total recovery
in the urine and feces were more than 95% of the administered dose
in rats and dogs (Sato et al., unpublished observations). In phase I
clinical trials, the plasma concentration and urinary excretion of
imidafenacin increased dose dependently in the range from 0.025 to
0.5 mg of single oral dose, and the apparent elimination half-life
ranged from 2.6 to 3.0 h (Shimada et al., 2007b). Accumulation of
imidafenacin in the plasma and urine was insignificant during multi-
ple oral administration of 0.25 mg twice a day (Shimada et al., 2007a).
Article, publication date, and citation information can be found at
http://dmd.aspetjournals.org.
doi:10.1124/dmd.107.016030.
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The purposes of this study were to determine the absorption and
excretion kinetics of imidafenacin in humans after oral administration
of [14C]imidafenacin and to investigate the metabolite profile of
imidafenacin in the plasma and excreta. Imidafenacin is supposed to
be transformed to many metabolites in humans; however, clinical
dosage is very low. In this case, a human mass-balance assay using
radiolabeled drugs is a valuable measure to elucidate the fate of
therapeutic drug in the body (Cox et al., 2000; Patrick et al., 2002;
Lantz et al., 2003; Minematsu et al., 2005). Accordingly, 14C-labeled
imidafenacin ([14C]imidafenacin, 14C-labeled position is shown in
Fig. 1) was administered oral at a dose of 0.25 mg (approximately 46
Ci) to six healthy male subjects, and the total radioactivity and
metabolite profile in plasma, urine, and feces were determined by a
LSC or HPLC connected to a RAD and MS/MS detectors. In addition,
chemical structures of two unique diol metabolites found in the
excreta were identified by comparison with those of the reference
product obtained from imidafenacin with the cupro-ascorbate oxida-
tion system.
Materials and Methods
Radiolabeled Material and Other Materials. [14C]Imidafenacin (Fig. 1)
was synthesized at GE Healthcare UK Ltd. (Little Chalfont, Buckinghamshire,
UK), with a certificate of analysis of the radiochemical purity (99.4%) and
specific activity (178 Ci/mg). [14C]Imidafenacin was stored at 80°C in the
dark. The radiochemical purity (more than 99.4%) and chemical authenticity of
[14C]imidafenacin was confirmed by HPLC before the study, after mock dose
preparation and administration to subjects. Authentic standards of imidafena-
cin and its metabolites M-1, M-2, M-3, M-4, M-5, M-6, M-8, M-9, and M-10
(Fig. 1) were prepared by chemical synthesis or isolation from biological
samples in our laboratory. All other reagents were of HPLC grade or analytical
grade and were obtained from commercial sources.
Dose Preparation. [14C]Imidafenacin was dissolved in ethanol, and the
radioactive concentration was determined. A certain volume of the [14C]imi-
dafenacin ethanolic solution was dispensed into the hard gelatin capsules
(equivalent to 0.25 mg and 46 Ci per capsule). Ethanol was evaporated under
a steady stream of nitrogen.
The radioactive dose was set according to human dosimetry calculations
established by the National Radiological Protection Board (Oxon, UK). Ad-
FIG. 1. Chemical structures of [14C]imi-
dafenacin and postulated metabolites, and
their fragment ions. , 14C labeled position;
broken line, precursor and product ions ob-
tained by collision-induced dissociation in
LC/MS/MS.
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ministration of [14C]imidafenacin for the radioactive medical product was
authorized by the Administration of Radioactive Substances Advisory Com-
mittee (Oxon, UK). The radiation exposure in this study, approximately 0.34
mSv, fell into category IIa studies (0.1–1 mSv) in the International Commis-
sion on Radiological Protection guidelines (1992). A single oral dose of 0.25
mg of imidafenacin has been known to be well tolerated in the phase I clinical
trials of nonradiolabeled imidafenacin.
Study Design. This study was an open-label and nonrandomized study
involving six healthy Caucasian male subjects, all of whom were to receive a
single oral dose of [14C]imidafenacin. The clinical phase of this study was
conducted at the clinical unit of Inveresk Research (Edinburgh, UK). This
study was performed in accordance with good clinical practice guidelines and
the Declaration of Helsinki. Before the start of study, the study protocol and
the informed consent documents were approved by an independent ethics
review committee. All of the subjects provided written informed consent
before the study.
The subjects were screened within 21 days before administration of
[14C]imidafenacin. The mean age of the subjects was 44.0 (from 32 to 53)
years, the mean height was 177.7 (from 168 to 185) cm, the mean weight was
82.43 (from 71.2 to 97.1) kg, and the mean body mass index was 26.08 (from
22.0 to 29.0) kg/m2. The subjects were admitted to the clinical unit on the day
before administration of [14C]imidafenacin, and a light supper was served at
approximately 11:00 PM. Neither food nor beverage was permitted after the
supper except for water. At approximately 8:30 AM on day 1 each subject was
administered a single oral dose of 0.25 mg of [14C]imidafenacin with approx-
imately 200 ml of water. Subjects fasted for approximately 4 h after admin-
istration, and then a light lunch was served. Safety evaluations including
physical examination, hematology and clinical chemistry analyses, urinalysis,
12-lead electrocardiogram, and vital signs were performed throughout the
admission period
Sample Collection. Blood samples were collected from an in situ venous
cannula or by venipuncture into lithium heparin tubes. From 10 to 20 ml of
blood samples were taken at the following times: 0 (before administration),
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 h after
administration. Blood samples were centrifuged for 10 min at approximately
4°C, and separated plasma was transferred into polypropylene tubes. Total
radioactivities in the samples were analyzed as soon as possible, and the
remainders of the samples were stored at approximately 80°C for metabolite
profiling.
Urine samples were collected for the following intervals: 0 (before admin-
istration), 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to
120, 120 to 144, and 144 to 168 h after administration. For one subject, urine
samples were collected until 192 h after administration because excretion of
radioactivity continued in the urine. Aliquots of each sample were transferred
into separate polypropylene tubes for analysis of the total radioactivity and
metabolite profiling, and then the samples were stored at approximately
20°C and at approximately 80°C, respectively.
Fecal samples were collected for the following intervals: 0 (before admin-
istration), 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144
to 168 h after administration. For one subject, fecal samples were collected
until 192 h after administration because excretion of radioactivity continued in
the feces. Fecal samples were homogenized in water, aliquots of each homog-
enate were retained in separate closed containers for analysis of the total
radioactivity and metabolite profiling, and the samples were stored at approx-
imately 20°C and at approximately 80°C, respectively.
Analysis of Total Radioactivities in Samples. Volumes or weights of all
samples were measured. Duplicate portions of plasma and urine samples were
diluted with water or compatible solvent and dissolved in liquid scintillation
fluid, Quickszint 1 (Zinsser Analytic, Maidenhead, UK). Duplicate portions of
fecal homogenate samples (approximately 0.3 g) were combusted using a
Tri-Carb 307 automatic sample oxidizer (Packard Biosciences Ltd., Pang-
bourne, UK). The 14CO2 generated was collected in the absorbing fluid,
Carbo-Sorb CO2 and scintillation fluid, Permafluor E
 (Packard Biosciences
Ltd.).
All of the samples in the scintillation fluid were subjected to liquid scintil-
lation counting for 5 min, together with representative blank samples, using an
LSC (Tri-Carb 2500TR; Packard Biosciences Ltd.) with automatic quench
correction by an external standard method. The limit of reliable measurement
was defined as 30 dpm above the background.
Calculation of Urinary and Fecal Excretion. The total radioactivities
excreted in the urine and feces were calculated by the time points after
administration of [14C]imidafenacin and are expressed as a percentage of the
administered radioactivity (percentage of dose).
Estimation of Pharmacokinetic Parameters. Pharmacokinetic parameters
were estimated using WinNonlin Professional (version 3.1; Pharsight, Moun-
tain View, CA). A noncompartmental approach was used to generate param-
eter estimates, using WinNonlin model 200 (extravascular input). All of the
total radioactivities calculated from data below the limit of reliable detection
(30 dpm above the background) were considered to be zero. The apparent
terminal elimination phase was identified by regression analysis with Win-
Nonlin, using data points from 24 to 168 h after administration.
The observed maximum concentration (Cmax) of the total radioactivity and
time at maximum concentration (Tmax) after administration were identified by
inspection of the total radioactivity versus time data. The area under the
concentration versus time curve from time 0 to t h (AUC0–t), where t indicates
the time point for the last sample in which the total radioactivity was reliably
quantified, was calculated using the linear trapezoidal method. The AUC0–inf,
area under the concentration versus time curve from time 0 to infinity, was
calculated as the sum of AUC0–t and Ct/Kel, where Ct indicates the total
radioactivity at t hours as mentioned above and Kel indicates the terminal
elimination rate constant determined from the slope of the terminal elimination
phase. The half-life of the terminal elimination phase (t1/2el) was calculated as
0.693/Kel.
Metabolite Profiling. Pretreatment of plasma. Plasma samples at 2 h
(approximately Tmax) and at 12 h (elimination phase) were selected as the
samples to assess the metabolic profile of imidafenacin. The radioactivity in
the latter sample was on the brink of the detection limit. The cryopreserved
plasma samples (2 and 12 h) were thawed, and designated amounts of the
plasma samples obtained from six subjects after administration of [14C]imi-
dafenacin were pooled. The pooled plasma was mixed with a 3-fold volume of
acetonitrile containing 1% acetic acid, sonicated for 5 min, and centrifuged at
1800g for 15 min at 4°C to separate the supernatant. The residue was reex-
tracted with the same solvent, followed by shaking and centrifugation. The
extraction recoveries were 84.5% for 2-h plasma and 73.5% for 12-h plasma.
Entire supernatants were combined and evaporated to dryness under re-
duced pressure, and the residue was reconstituted in 0.3% formic acid in
water-acetonitrile (90:10, v/v) and centrifuged at 1800g for 5 min at 4°C. The
supernatant was filtered (0.45 m), and an aliquot of the filtrate was analyzed
under the conditions described below.
Pretreatment of urine and feces. The cryopreserved urine samples (0–4 and
4–24 h) were thawed, and the samples obtained from six subjects after
administration of [14C]imidafenacin were pooled at the sample volume ratio.
The cryopreserved fecal homogenates (0–48 and 48–96 h) were thawed, and
the homogenates containing radioactivity of 2% or more of the administered
dose, prepared from six subjects after administration of [14C]imidafenacin,
were pooled at the sample weight ratio. An aliquot of the pooled sample was
mixed with a 3-fold volume of methanol, shaken for 10 min, and centrifuged
at 1800g for 10 min at 4°C to separate the supernatant. The residue was
reextracted with methanol, followed by shaking and centrifugation. The ex-
traction recoveries were 93.1% for 0- to 4-h urine, 88.6% for 4- to 24-h urine,
77.2% for 0- to 48-h feces, and 69.2% for 48- to 96-h feces.
Entire supernatants were combined and evaporated to dryness under re-
duced pressure. The residue was reconstituted in 0.3% formic acid in water-
acetonitrile (90:10, v/v), and an aliquot of the solution was analyzed under the
conditions described below. The reconstituted fecal solution was centrifuged at
1800g for 5 min at 4°C. The supernatant was filtered (0.45 m), and an aliquot
of the filtrate was analyzed under the conditions described below.
Analysis of metabolites in samples. Relative amounts of metabolites in the
plasma, urine, and feces were determined by HPLC connected to a RAD or by
a LSC after collection of HPLC eluates. The metabolites were identified by
comparison of retention times between radioactive peaks and ion peaks on the
high-performance liquid chromatograph connected to the MS/MS system.
An TSKgel Octyl-80Ts column (5 m, 4.6 mm i.d.  150 mm in length;
Tosoh Corp., Tokyo, Japan) connected to a guard column was used as the LC
column. As the mobile phase, the mixture of 0.3% formic acid in water-
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acetonitrile (90:10, v/v) (A) and 0.7% formic acid in acetonitrile (B) was
flowed at 1 ml/min in the following linear gradient mode: starting with 0% of
B composition to 5 min, increasing to 10% in 5 to 10 min, increasing to 18%
in 10 to 30 min, and finally increasing to 100% in 30 to 35 min and maintaining
100% in 35 to 40 min. The column was maintained at room temperature. The
column eluate was split in the ratio of approximately 4:1 and introduced to the
RAD, (FLO-ONE/525TR; Packard Biosciences Ltd.) and the mass spectrom-
eter (TSQ7000; Thermo Electron Corporation, Waltham, MA), respectively.
As scintillation fluid for the RAD, Flo-Scint II (Packard Biosciences Ltd.) was
delivered to the HPLC eluate at a 3-fold flow rate of the mobile phase, and the
radioactivity was monitored using the RAD with 6-s integration. For the
sensitive detection of radioactivity in plasma, the HPLC eluates were collected
every 18 s and dissolved in liquid scintillation fluid (Hionic-Fluor; Packard
Biosciences Ltd.), and then the radioactivity in each fraction was detected for
2 min using the LSC (Tri-Carb 2500TR; Packard Biosciences Ltd.). Detection
limits of radioactivity in metabolite peaks in the RAD and LSC assays were
defined as 3 and 2 times the background values, respectively.
For ionization and detection of all analytes, the conditions of the TSQ7000
equipped with ESI interface were positive ionization mode, spray voltage at
4.5 kV, capillary temperature at 290°C, multiplier voltage at 1500 V, sheath
gas pressure at 70 psi (N2), auxiliary gas flow at 10 arbitrary units (N2),
collision gas pressure at 2.0 mTorr (Ar), and collision energy at 18 to 30 eV.
The precursor and product ions monitored in SRM, as shown in Fig. 1, were
m/z 3223240 for [14C]imidafenacin, 3383240 for [14C]M-1, 3543240 for
[14C]M-2, 3563240 for [14C]M-3, 3283193 for [14C]M-4, 3293193
for [14C]M-5, 2403117 for [14C]M-6, 3443209 for [14C]M-8, 4983240 for
[14C]M-9, 2983240 for [14C]M-10, and 5143240 for postulated metabolites.
Data processing. The ratio of counts of each radioactive peak to the total
radioactivity counts over run time (percentage on HPLC) was obtained and
multiplied by the extraction recovery through the pretreatment of samples to
determine the compositions of metabolites to the radioactivities in the plasma,
urine, and feces (percentage in sample). The metabolite concentrations in the
plasma were calculated from the mean values of the total radioactivity in six
subjects and are expressed as equivalents of imidafenacin (nanogram equiva-
lents of imidafenacin per milliliter). The radioactivities of the metabolites
excreted in the urine and feces were calculated from the mean values of the
total radioactivities excreted in six subjects and are expressed as a percentage
of the mean radioactivity administered (% dose).
Identification of M-11 (M-11a and M-11b). Synthesis and purification of
reference products. Imidafenacin was chemically oxidized in the cupro-ascor-
bate system to obtain the reference product for two unknown metabolites found
in the urine and feces. To 20 ml each of 100 mM imidafenacin methanolic
solution, 0.5 M L-()-ascorbate solution, and 5 mM copper chloride solution
were added 2 liters of 0.1 M phosphate buffer solution (pH 7.2), and the
mixture was stirred for 24 h at room temperature. After washing three times
with 1 liter of chloroform, an aqueous layer was lyophilized and concentrated.
The reference products were semipurified as the major constituent-rich fraction
and the minor constituent-rich fraction by sequential column chromatography
with Chromatorex ODS (Fuji Silysia Chemical Ltd., Aichi, Japan) and Wakosil
25C18 (Wako Pure Chemical Industries Ltd., Osaka, Japan) columns, eluting
with the mixture of water and acetonitrile containing 0.05 or 0.1% formic acid.
Structural elucidation of reference products. The reference products were
dissolved in NMR grade D2O (Sigma-Aldrich, St. Louis, MO) spiked with
3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid, sodium salt (Sigma-Aldrich) as an
internal reference for the chemical shift. The 1H NMR and 13C NMR spectra
were measured on the JNM EX-400 spectrophotometer (JEOL, Tokyo, Japan)
for the structural elucidation of the reference products. In addition, the nuclear
Overhauser effect, DEPT, 1H-1H COSY, HMQC, and HMBC spectra were
also acquired for further assignment of proton and carbon signals.
The reference products were dissolved in the mixture of water and aceto-
nitrile or D2O and acetonitrile. Then the solution was injected into the MS/MS
system comprising an API-4000 mass spectrometer equipped with an ESI
interface (Applied Biosystems/MDS Sciex, Foster City, CA) at the constant
rate of 3 l/min to determine precursor and product ion spectra of the reference
products.
Identification of M-11 in human urine. Using a high-performance liquid
chromatograph connected to the MS/MS system comprising the API-4000
mass spectrometer equipped with an ESI interface, the retention time and
product ion spectra of reference products were compared with those of un-
known metabolites in human urine collected at 2 to 4 h after a single oral
administration of nonradiolabeled imidafenacin. A TSKgel ODS-80Ts column
(5 m, 2.0 mm i.d.  150 mm in length, Tosoh Corp.) connected to a guard
column was used as the semimicro LC column. As the mobile phase, the
mixture of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile
(B) was flowed at 0.2 ml/min in the following linear gradient mode: starting
with 10% of B composition to 5 min, increasing to 19% in 5 to 10 min,
increasing to 26% in 10 to 30 min, and finally increasing to 91% in 30 to 35
TABLE 1
Pharmacokinetic parameters of total radioactivity in plasma after a single p.o.
administration of 0.25 mg of 14Cimidafenacin in six healthy male subjects
Parameters Mean S.D.
Cmax (pg Eq/ml) 3860 723
Tmax (h) 1.50 0.45
t1/2el (h) 72.11 6.54
AUC0–t (ng Eq  h/ml) 69.09 7.63
AUC0–inf (ng Eq  h/ml) 83.06 10.18
FIG. 2. Total radioactivity in plasma after a single oral administration of 0.25 mg
of [14C]imidafenacin in six healthy male subjects. Each point represents the mean 
S.D. of six individuals.
FIG. 3. Urinary and fecal recovery of total radioactivity in urine and feces after a
single oral administration of 0.25 mg of [14C]imidafenacin in six healthy male
subjects. Each point represents the mean  S.D. of six individuals.
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min and maintaining 91% in 35 to 40 min. The column was maintained at room
temperature.
Stability of reference products. The reference products were dissolved in
water or 100 mM phosphate buffer (pH 7.2) and then were allowed to stand at
room temperature or incubated at 50°C for 5 h. After incubation, the ratio of
the major and minor constituents of the reference products or their decomposed
product, amidine form M-10, was measured by HPLC. A TSKgel ODS-80TM
column (5 m, 4.6 mm i.d.  150 mm in length, Tosoh Corp.) connected to
a guard column was used as the LC column. As the mobile phase, 0.1% formic
acid in water-0.1% formic acid in acetonitrile (73:27, v/v) was flowed at 1
ml/min. The column was maintained at room temperature. The analytes were
detected by ultraviolet absorption at 210 nm.
Results
Safety Assessment. Six subjects were given a single oral dose of
0.25 mg of [14C]imidafenacin. No serious adverse events were re-
ported, and no subjects were withdrawn from the study because of
adverse events.
Radioactivity in Plasma. The total radioactivity in the plasma is
shown in Fig. 2, and the pharmacokinetic parameters are summarized
in Table 1. After oral administration of 0.25 mg of [14C]imidafenacin,
Cmax, the mean of the maximum concentration of the total radioac-
tivity in the plasma, was 3860 pg Eq/ml (from 3230 to 5210 pg Eq/ml)
at 1.50 h after administration (Tmax, from 1.00 to 2.00 h). Plasma
concentrations decreased rapidly to the mean of 598 pg Eq/ml by 24 h
and then gradually decreased to 133 pg Eq/ml by 168 h after admin-
istration. The mean of t1/2el, estimated from 24 to 168 h after admin-
istration, was 72.11 h. The means of AUC0–t and AUC0–inf were
69.09 ng Eq  h/ml (from 60.59 to 81.11 ng Eq  h/ml) and 83.06 ng
Eq  h/ml (from 73.45 to 101.2 ng Eq  h/ml), respectively.
Urinary and Fecal Excretion of Radioactivity. Urinary and fecal
recoveries of the total radioactivity in the urine and feces are shown
in Fig. 3. After oral administration of 0.25 mg of [14C]imidafenacin,
urinary excretion accounted for 62.5% of the administered dose by
48 h after administration and the mean of 65.6% (from 62.6 to 69.3%)
of the administered dose by the end of the collection period, 192 h
after administration, demonstrating that radioactivity was excreted
primarily in the urine. Fecal excretion accounted for the mean of
29.4% (from 27.6 to 31.3%) of the administered dose. Recovery of the
total radioactivity was quantitative with the mean of 95.0% (from 91.3
to 98.3%) of the administered dose by 192 h after administration.
Metabolite Profiles. HPLC radiochromatograms of imidafenacin
and its metabolites in the plasma, urine, and feces are shown in Figs.
4, 5, and 6. The metabolites were identified by comparison of reten-
tion times between radioactive peaks and ion peaks on the LC/MS/MS
chromatogram. Relative amounts of metabolites in the plasma, urine,
and feces are summarized in Table 2. M-6 and M-8 were not found in
all samples determined.
In the 2- and 12-h plasma (Fig. 4; Table 2), the concentrations of
unchanged imidafenacin were 1.19 ng Eq/ml (equivalent to 33.3% of
the radioactivity in the plasma) and 0.12 ng Eq/ml (10.7%), respec-
tively. In the 2-h plasma, a major metabolite M-9 was detected, and
then M-2 and M-4 and a minor metabolite M-3 and a mixture of a
minor metabolite M-10 and unknown metabolite HP1 (identified as
FIG. 4. HPLC radiochromatograms of imidafenacin and its metabolites in pooled
plasma after a single oral administration of 0.25 mg of [14C]imidafenacin in six
healthy male subjects.
FIG. 5. HPLC radiochromatograms of imidafenacin and its metabolites in pooled
urine after a single oral administration of 0.25 mg of [14C]imidafenacin in six
healthy male subjects.
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M-11b) were detected. In the 12-h plasma, a major metabolite M-4
and minor metabolites M-2 and M-9 were detected.
In the 0- to 4- and 4- to 24-h urine (Fig. 5; Table 2), unchanged
imidafenacin accounted for 2.9% of the administered dose (equivalent
to 14.2% of the radioactivity in the urine) and 5.1% (13.9%), respec-
tively. In the 0- to 4-h urine, M-2, a mixture of M-9 and an unknown
metabolite HU2 (identified as M-11a), and an unknown metabolite
HU3 (identified as M-11b) were mainly detected, accounting for 2.6
to 4.8% of the dose (equivalent to 13.0–23.6% of the radioactivity in
urine). In the 4- to 24-h urine, M-2, a mixture of M-9 and HU2, and
HU3 were also mainly detected, accounting for 4.6 to 9.1% of the
dose (12.4–24.9%). Minor unknown metabolite HU1 detected by
SRM would be a glucuronide of mono-oxygenated imidafenacin (m/z
5143240).
In the 0- to 48- and 48- to 96-h feces (Fig. 6; Table 2), unchanged
imidafenacin was not detected. In the 0- to 48-h feces, M-2, M-10, an
unknown metabolite HF2 (identified as M-11a), and an unknown
metabolite HF3 (identified as M-11b) were mainly detected, account-
ing for 1.0 to 3.9% of the administered dose (equivalent to 5.7–21.9%
of the radioactivity in the feces). In the 48- to 96-h feces, M-2 and
HF3 accounted for 1.3 and 1.2%, respectively. There were several
unknown metabolite peaks in the 0- to 48- and 48- to 96-h feces,
accounting for 1.2% or less of the administered dose (9.5% or less).
Identification of M-11 (M-11a and M-11b). Two major unknown
metabolites at 16.8 to 17.1 min (HU2 and HF2) and 18.3 to 18.9 min
(HP1, HU3, and HF3) were found in the urine and feces and were
detected by SRM as identical m/z 3563240 transitions (Table 2). The
product ion (m/z 240) indicated a 14C-labeled 2,2-diphenylbutanamide
moiety, which was identical to that of [14C]imidafenacin; therefore,
according to the precursor ion (m/z 356), the 2-methylimidazole
moiety of [14C]imidafenacin would be modified by adding 34 Da to
form these unknown metabolites. However, absolute amounts of these
metabolites in human urine and feces were not enough to elucidate
their chemical structures. Accordingly, imidafenacin was oxidized in
the cupro-ascorbate system to obtain the reference products, its oxides
TABLE 2
Compositions of imidafenacin and its metabolites in plasma, urine, and feces after a single p.o. administration of 0.25 mg of 14Cimidafenacin in
healthy male subjects
Numbers in parentheses denote percentage of total radioactivity in samples.
Metabolites Mass Transition Retention Time
Plasma Urine Feces
2 h 12 h 0–4 h 4–24 h 0–48 h 48–96 h
m/z min ng Eq/ml % dose
Imidafenacin 3223240 21.3–21.7 1.19 (33.3) 0.12 (10.7) 2.9 (14.2) 5.1 (13.9) — —
M-1 3383240 23.7 — — 0.3 (1.4) 0.2 (0.5) — —
M-2 3543240 26.9–27.0 0.34 (9.5) 0.09 (7.6) 2.6 (13.0) 4.6 (12.4) 1.8 (9.9) 1.3 (10.9)
M-3 3563240 22.6–22.8 0.15 (4.1) — 0.3 (1.3) 0.7 (1.9) — —
M-4 3283193 28.7–28.8 0.34 (9.4) 0.21 (18.0) 0.1 (0.5) 1.3 (3.6) — —
M-5 3293193 24.6–24.7 — — 0.5 (2.6) 1.8 (5.0) — —
M-9 4983240 16.8–17.1 0.63 (17.6) 0.11 (9.9) 4.8 (23.6)a 9.1 (24.9)a — —
M-10 2983240 18.7–19.4 0.28 (7.9)b — 0.7 (3.7) 0.7 (1.9) 1.0 (5.7) 0.6 (4.7)
HU2, HF2 (M-11a) 3563240 16.8–17.1 — — 4.8 (23.6)a 9.1 (24.9)a 1.1 (6.2) 0.3 (2.8)
HP1, HU3, HF3 (M-11b) 3563240 18.3–18.9 0.28 (7.9)b — 4.6 (22.6) 5.5 (14.9) 3.9 (21.9) 1.2 (9.7)
HU1 5143240 15.2–15.3 — — 1.1 (5.6) 2.0 (5.4) — —
HF1 — 14.7–15.0 — — — — 0.6 (3.3) 0.2 (1.4)
HF4 — 20.2–20.3 — — — — 0.3 (1.7) 0.8 (6.4)
HF5 — 21.5 — — — — 0.6 (3.3) 0.6 (4.8)
HF6 — 22.2 — — — — 0.9 (5.1) 0.2 (1.9)
HF7 — 22.7–22.9 — — — — 0.2 (0.9) 0.2 (1.5)
HF8 — 34.2–34.3 — — — — 0.9 (4.8) 1.2 (9.5)
Others N.C. (2.7) N.C. (27.3) 2.3 (11.5) 5.7 (15.6) 6.6 (22.8) 5.7 (30.8)
Total 3.57 (84.5) 1.16 (73.5) 20.2 (100) 36.7 (100) 17.9 (85.6) 12.3 (84.4)
—, not detected; N.C., not calculated.
a Total amount of M-9 and HU2.
b Total amount of M-10 and HP1.
FIG. 6. HPLC radiochromatograms of imidafenacin and its metabolites in pooled
feces after a single oral administration of 0.25 mg of [14C]imidafenacin in six
healthy male subjects.
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of the 2-methylimidazole moiety as reported by Ohta et al. (1998).
Then, the mass spectra of the reference products were compared with
those of the unknown metabolites in human urine.
Structural elucidation of the reference products was achieved by
analyses of one- and two-dimensional NMR spectra including 1H-1H
COSY, HMQC, HMBC, DEPT, and nuclear Overhauser effect. 1H
and 13C NMR assignments for the reference products are shown in
Table 3. Because those reference products were mixtures of the major
and minor constituents in each fraction, signals of H-1, H-5, and H-6
protons and C-1, C-2, C-3, C-5, C-6, and C-11 carbons in the major
and minor constituents were observed in the spectra of both fractions.
The oxygenated 2-methylimidazole moiety was analyzed as follows.
The presence of two oxygenated methine carbons (87.61 and 93.10
ppm) was supported by DEPT spectra. The proton signals (5.26 and
5.33 ppm) on these oxy-methine carbons were deduced from HMQC
analysis, and the neighboring connectivity of these two oxy-methines
was analyzed by direct coupling between protons at 5.26 and 5.33
ppm from 1H-1H COSY spectra. Furthermore, the HMBC correlations
between three protons (H-1, H-5, and H-6) and the sp2 carbon signal
at 170.8 ppm (C-11) suggested the presence of a five-membered ring.
These findings corroborated the hypothesis that the reference products
were obtained by the oxidation of C-5 and C-6 carbons in imidafe-
nacin.
Product ion spectra of reference products dissolved in water and
acetonitrile or D2O and acetonitrile are shown in Fig. 7. Product ion
spectra of reference products (m/z 354) and deuterium-displaced ref-
erence products (m/z 359) suggested that the reference products had
two deuterium-displaceable hydrogens, such as hydroxyl groups on
C-5 and C-6 carbons in the 2-methylimidazole moiety of imidafena-
cin, as indicated in Fig. 7.
1H NMR spectra showed vicinal proton-proton coupling (J  8.1
Hz) on doublet signals of H-5 and H-6 protons in the minor constit-
uent. According to the Karplus (1963) equation, the dihedral angle
between vicinal protons attached to neighboring C-5 and C-6 carbons
was approximately 0°. In contrast, H-5 and H-6 protons in the major
constituent were singlet signals, indicating orthogonal protons at-
tached to C-5 and C-6 carbons. Consequently, structures of the major
and minor constituents of the reference products were estimated to be
trans- and cis-isomers of diol forms, respectively.
The LC/MS/MS chromatogram on SRM at m/z 3543238 of human
urine and the reference products are shown in Fig. 8. Product ion
spectra of m/z 354 derived from two unknown metabolites, HU2 and
HU3, in human urine, and the major and minor constituents of
reference products are shown in Fig. 9. The LC/MS/MS retention time
and product ion spectra of HU2 and HU3 in the urine collected at 2 to
TABLE 3
Chemical shifts of protons and carbons in 1H NMR and 13C NMR spectra of
major (M-11b) and minor (M-11a) constituents of reference products
obtained from imidafenacin
Position of Proton
1H NMR Data (in D2O)
Major Constituent (M-11b) Minor Constituent (M-11a)
1 2.18a (3Hb, sc) 2.11a (3Hb, sc)
2 2.82 (2H, m) 2.79 (2H, m)
3 3.45 (2H, m) 3.41 (2H, m)
5 5.26 (1H, s) 5.43–5.47d (1H, d, J  8.1e)
6 5.33 (1H, s) 5.43–5.47d (1H, d, J  8.1e)
8, 9, and 10 7.39–7.49 (10H, m) 7.40–7.48 (10H, m)
13 8.45 (1.3H, s) 8.45 (2H, s)
Position of Carbon
13C-NMR Data (in D2O)xc





5 87.61 80.22 or 85.78f
6 93.10 80.22 or 85.78f
7 144.2–144.4f 144.2–144.4f




a Chemical shifts are reported in parts per million.
b Intensities are represented as number of protons.
c Multiplicity: s, singlet; d, doublet; m, multiplet.
d These proton signals could not be distinguished.
e Coupling constants (J) are given in Hertz.
f These carbon signals could not be distinguished.
FIG. 7. Product ion spectra of reference products obtained by the cupro-ascorbate
oxidation system with or without deuterium displacement.
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4 h after a single oral administration of imidafenacin corresponded to
those of the minor and major constituents of reference products,
respectively. From these results, HU2 and HF2 were identified as the
cis-isomer (M-11a), and HP1, HU3, and HF3 were identified as the
trans-isomer (M-11b) of the diol form.
After the reference products were allowed to stand at room tem-
perature for 5 h in water or 100 mM phosphate buffer (pH 7.2), the
ratio of the minor to major constituents remained unchanged, that is,
approximately 30% based on the calculation of peak areas on the
HPLC chromatogram. After incubation at 50°C for 5 h, however, peak
areas of both constituents decreased and the decomposed product,
amidine form M-10, increased to more than 30% of the initial peak
area of both constituents. After NMR measurements, the ratio of the
major constituent increased even in the minor constituent-rich frac-
tion. These findings suggested that the major and minor constituents
might be interchangeable and gradually decomposed to the amidine
form under heating conditions.
Discussion
In the present study, the absorption and excretion kinetics and
metabolic profile of imidafenacin were investigated in six healthy
male subjects after a single oral administration of 0.25 mg of
[14C]imidafenacin. Unknown metabolites found in the excreta were
identified by LC/MS/MS and NMR analyses.
The highest total radioactivity in the plasma was observed at 1.50 h
after administration, which was consistent with rapid absorption of the
oral dose of imidafenacin in humans (Fig. 2; Table 1). These findings
are supported by the results in the preclinical toxicological studies in
rats and dogs, demonstrating that the total radioactivity in the plasma
peaked within 2.0 h after oral administration of [14C]imidafenacin.
Furthermore, 65.6% of the administered dose of radioactivity was
detected in the urine (Fig. 3), suggesting that no less than a 65.6%
dose of imidafenacin would be absorbed from the gut. This finding is
FIG. 8. LC/MS/MS chromatograms on SRM at m/z 3543238 of human urine and
reference products obtained from imidafenacin.
FIG. 9. Product ion spectra of m/z 354 derived from unknown metabolites, HU2 and
HU3, in human urine, and major and minor constituents of reference products
obtained from imidafenacin.
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consistent with the absolute bioavailability of 57.8% after intravenous
administration of imidafenacin in humans (Ohno et al., 2007). The
bioavailability of humans was larger than that of rat (5.3%) and dog
(36.1%) (Masuda et al., unpublished observations).
In contrast with the rapid increase in radioactivity in the plasma, the
radioactivity gradually decreased from 24 to 168 h after administra-
tion, with a relatively long t1/2el of 72.11 h (Fig. 2; Table 1). On the
metabolite profiling, major components of radioactivity were un-
changed imidafenacin and M-9 (50.9% in total) in the 2-h plasma and
M-4 (18.0%) in the 12-h plasma (Fig. 4; Table 2). M-4 and related
minor metabolites might contribute to the relatively long t1/2el of
radioactivity in the plasma. Approximately 65.6 and 29.4% of the
administered dose of [14C]imidafenacin were excreted via urine and
feces, respectively, within 192 h after administration (Fig. 3). The
total recovery of radioactivity reached 95.0% of the administered
dose. In the preclinical toxicological studies, urinary and fecal recov-
eries of oral administered [14C]imidafenacin were 18.2 and 77.0%,
respectively, in rats, and 44.8 and 51.6%, respectively, in dogs (Ooie
et al., unpublished observations). From these data, oral administered
imidafenacin was thoroughly excreted via urine and feces in all of the
species studied, despite differences in the main excretion route among
the species.
After oral administration to humans, imidafenacin underwent dif-
ferent metabolic transformations, including N-glucuronide conjuga-
tion (M-9) and oxidation of the 2-methylimidazole moiety (M-1, M-2,
M-11a, and M-11b) or the ring cleavage (M-3, M-4, M-5, and M-10);
the metabolic activity for N-glucuronidation, in particular, was found
to be relatively high. The metabolic pathway of imidafenacin for
N-glucuronidation, however, was uncommon in rats and dogs, and rats
have the unique metabolic pathway for the oxidation on the phenyl
moiety, generating M-8 and its related metabolites (Sato et al., un-
published observations). Species differences for N-glucuronidation
were also observed in afloqualone in common with imidafenacin,
indicating high N-glucuronidation activity in humans compared with
activity in experimental animals except rabbits (Green and Tephly,
1998; Kaji and Kume, 2005).
On the basis of the metabolites found in the plasma, major
metabolites of imidafenacin were M-2, M-4, and M-9, accounting
for approximately 10% or more of the total radioactivity in the 2-
or 12-h plasma (Fig. 4; Table 2). It has been reported that M-2,
M-4, and M-9 had low affinities for muscarinic receptors, whereas
unchanged imidafenacin had high affinity for muscarinic receptor
subtypes M1 and M3 (Kobayashi et al., 2007a). These findings
suggest that the in vivo anticholinergic effects of oral administered
imidafenacin would result from the unchanged form alone. In
addition, toxicological symptoms attributable to M-2 and M-4 after
oral administration of imidafenacin and to M-9 after intravenous
administration of M-9 were insignificant in the preclinical studies
(Kasai et al., unpublished observations), and the inhibitory poten-
tials of these metabolites on cytochrome 450 isozymes were ex-
tremely low (Kanayama et al., 2007). In the meantime, because
imidafenacin was metabolized by UGT1A4 to form M-9 and by
CYP3A4 to form M-2 and M-4, metabolism of imidafenacin might
be inhibited by concomitant administration of drugs with an in-
hibitory potential on CYP3A4 or UGT1A4 (Kanayama et al.,
2007).
We identified interchangeable diol-form metabolites, M-11a and
M-11b, in the urine and feces (Fig. 7). Because the minor constituent
of the diol-form metabolite, cis-isomer (M-11a), was readily inter-
changeable to the major constituent, trans-isomer (M-11b), up to
approximately 30% of the trans-isomer was found in the minor
constituent-rich fraction. Furthermore, M-11a and M-11b decom-
posed to the amidine form M-10 under heating conditions. However,
M-10 was rarely detected in human plasma, urine, and feces, probably
because the samples for metabolite profiling were treated under cool-
ing conditions during storage and pretreatment throughout the study.
A similar metabolic pathway has been reported in a hypoglycemic
argent, midaglizole. That is, midaglizole was oxidized and hydrated at
a 2-substituted-imidazole moiety to form a 4,5-dihydro-diol interme-
diate, although its stereochemistry was unknown, and then amidine
metabolites were obtained by a ring-opening reaction (Nakaoka and
Hakusui, 1987). However, this intermediate metabolite was not iso-
lated and identified owing to its instability. In contrast, the 4,5-
dihydro-diol metabolites of imidafenacin, M-11a and M-11b, were
relatively stable in the biological samples during storage and pretreat-
ment, whereas their absolute amounts were too small to isolate for
structural elucidation. Therefore, M-11a and M-11b were successfully
identified by obtaining the reference product from imidafenacin with
oxidation in the cupro-ascorbate system.
In conclusion, the present study clarified the absorption and excre-
tion kinetics of imidafenacin and the characteristics of metabolites in
the plasma and excreta in six healthy male subjects after a single oral
administration of 0.25 mg of [14C]imidafenacin. The results indicate
that imidafenacin is rapidly and well absorbed after oral administra-
tion and circulates in the plasma as the unchanged form, its glucuro-
nide conjugate, and other metabolites, and then is excreted primarily
in the urine and feces as the oxidized metabolites of the 2-methylimi-
dazole moiety. For treatment of overactive bladder, imidafenacin is
expected to provide suitable anticholinergic effects through its excel-
lent pharmacokinetic properties in humans verified in the present
study.
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